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Abstract: This review summarizes the current research and outlooks regarding the obstacles 
to diagnosing and treating early alpha-1-antitrypsin deficiency (AATD). It draws on prior 
systematic reviews and expert surveys to discover precisely what difficulties exist in early 
diagnosis and treatment of AATD and elucidate potential solutions to ease these difficulties. 
The perceived rarity of AATD may translate to a condition poorly understood by primary 
care physicians, and even many respiratory physicians, which results in opportunities for 
diagnosis being missed, especially in mild or asymptomatic patients. There are diagnostic 
techniques involving biomarkers and home testing methods which could improve the rate of 
early diagnosis. With respect to treatment, AATD involves treating two separate pathologies, 
lung disease and liver disease. The only specific AATD treatment, augmentation therapy, has 
proven ability in treating lung disease but not liver disease. Alpha-1-antitrypsin (AAT) 
synthesized in the liver can form damaging polymers that also result in reduced circulating 
AAT levels and, whilst liver transplantation is used to effectively treat AATD, it is inap-
propriate in early disease. Novel therapeutic areas such as gene editing and increasing 
autophagy are therefore being researched as future treatments. Ultimately, diagnosis and 
treatment are intrinsically linked in AATD, with earlier diagnosis leading to better treatment 
options and thus better patient outcomes. 
Keywords: emphysema, cirrhosis, diagnostic screening programs, chronic obstructive 
pulmonary disease
Introduction
Alpha-1-antitrypsin deficiency (AATD) is a hereditary, metabolic disorder that is 
defined by low serum concentration of the protease inhibitor, alpha-1-antitrypsin 
(AAT).1 In patients with AATD, the lack of AAT causes an imbalance in protease- 
antiprotease activity, this imbalance is the main factor in the pathogenesis of the 
disease.2 AAT normally acts to counteract serine proteases, such as neutrophil 
elastase, from causing proteolytic damage to the lungs. In deficient individuals 
this proteolysis continues unchecked and thus degrades elastin, compromising 
alveolar structure.2 The continued progression of this mechanism of action will 
eventually lead to the clinical presentation of symptoms of chronic obstructive 
pulmonary disease (COPD).2
AAT is encoded by the SERPINA1 gene and it is mutations on this gene that 
cause deficiency. AATD is a codominant condition and the severity of deficiency is 
dependent on the inherited genotype.3 There have been over 100 mutations 
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described in the literature, each with varying levels of 
deficiency and consequently pathogenicity.3 This includes 
null variants, which are mutations that can lead to a stop 
codon being transcribed so no functional protein is synthe-
sized. The normal allele is designated M and the normal 
genotype designated PiMM, with Pi representing protease 
inhibitor. This genotype codes for normal AAT serum 
concentrations, which are commonly accepted to be 1.0– 
2.2 g/L or 20–53 µM.4 The most common deficient alleles 
are S and Z, which code for roughly 60% and 15%, 
respectively, of normal AAT serum concentrations.4 
AATD is widely known in Europe as a disease of the 
Caucasian population but a comprehensive review of the 
prevalence of the S and Z alleles showed that the spread 
by migrating populations means they are found in many 
countries around the world.5 Prevalence varies within a 
given geographical region, and neighboring countries can 
often have widely different incidences. High incidence of 
the Z allele was seen in North Africa (28.6 per 1,000 
population in Egypt) and North/Central Asia (15.0 per 
1,000 population in Saudi Arabia) but none detected in 
Central/South Africa. The prevalence of AATD in the 
Brazilian population, which is known to be racially diverse 
and includes European immigrants, has been shown to be 
2.8%, which is similar to other countries, with the Z allele 
found in 0.8%.6 The S allele has been found in high 
numbers in at least nine South American countries, 
where numbers of greater than 30 per 1,000 population 
were observed.
PiSZ and PiZZ are the most commonly occurring gen-
otypes that are linked with the highest pathogenicity, 
although those heterozygous with M and Z/null can carry 
higher risk if they also have certain exposures, ie, 
smoking.7 Increasing evidence suggests that the SZ variant 
may also only lead to significant disease in the presence of 
such exposures.8,9
Those who are homozygous for PiZZ can also present 
with liver disease. This is because the Z allele leads to 
severe misfolding of the protein, and as AAT is secreted 
from hepatocytes the misfolded protein polymerizes caus-
ing hepatocyte damage. The pathophysiology for this 
damage is believed to originate primarily from stress in 
the endoplasmic reticulum due to accumulation of Z-AAT. 
Continuous hepatocyte destruction eventually manifests as 
chronic liver disease, initially fibrosis and eventually 
cirrhosis.10
There is increasing interest in both the pulmonary and 
hepatology literature in early diagnosis of COPD11 and 
liver fibrosis,12 respectively, with the hope that early diag-
nosis, lifestyle modifications, and aggressive treatment 
could reduce progression to more symptomatic disease, 
with consequent morbidity and reduced life expectancy. 
Since AATD may cause both of these problems, and onset 
of disease tends to be at a younger age than in non-AATD 
related disease, it is logical that the healthcare community 
would wish to prioritize early diagnosis in these indivi-
duals. The aim of this review is to collate and condense 
from the current literature factors seen as the main obsta-
cles to early diagnosis and management of AATD. In 
constructing this review, we used the 2017 European 
Respiratory Society (ERS) working statement on the diag-
nosis and treatment of AATD as a starting point.13 This 
was an update on the international statement published by 
ERS, in conjunction with the American Thoracic Society 
(ATS) some years previously,14 and focused on the diag-
nosis and treatment of AATD and associated lung disease, 
using systematic review methodology to identify literature 
up to that point. Subsequent targeted literature searches 
focused on systematic reviews, expert surveys, and rando-
mized controlled trials (RCTs) that might contain data on 
early diagnosis or treatment that were published after this 
review.
Diagnosis
When is AATD Diagnosed?
There are three main approaches adopted in the diagnosis 
of AATD; testing individuals who are symptomatic for 
AATD related pathology, ie, lung or liver disease, testing 
of individuals who may be genetically predisposed to 
AATD, and screening.13 Guidelines for testing have been 
laid out by the World Health Organization (WHO) via 
their 2014 Global Initiative for COPD which recommend 
routine testing for all COPD patients in areas with high 
AATD prevalence.15 The American Thoracic Society/ 
European Respiratory Society (ATS/ERS)14 went further, 
stating testing for AATD should be conducted for all 
COPD patients, all patients with unresponsive adolescent 
asthma, and all patients with either cryptogenic liver dis-
ease, granulomatosis with polyangiitis, bronchiectasis, or 
panniculitis. Traditionally, however, testing has only been 
carried out on individuals presenting with early onset 
emphysema. This diagnostic pathway has resulted in 
AATD being a condition which is likely both underdiag-
nosed and diagnosed too late for some therapeutic inter-
ventions to have maximum effect.
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Underdiagnosis of AATD
A recent update to a paper calculating the prevalence of 
PiZZ AATD in Europe, through secondary analysis of 
cohort studies, found prevalence to be approximately 
0.02–0.05%, which equates to a potential cohort of 
119,594 individuals.16 Data was collected from studies 
considered to be representative of the general population, 
with cohort studies of patients with AATD-related diseases 
such as COPD and liver cirrhosis excluded. In this work, 
the authors noted the substantial gap in epidemiological 
data surrounding AATD which highlights the underdiag-
nosed nature of the condition. There have been several 
recent papers, with wide scope, that have reported under-
diagnosis of AATD.17,18 Several different factors have 
been hypothesized to try and explain this, ranging from 
the wide variability in AATD pathogenicity which makes 
definitive diagnosis difficult, to the fact that the usual 
clinical presentation of AATD is very similar to COPD 
and therefore may be misdiagnosed. A Europe-wide sur-
vey of experts in AATD found that underdiagnosis is a key 
problem in the management of AATD; most clinicians 
(77%) believed that only about 15% of cases of AATD 
were being diagnosed, with the remainder surveyed esti-
mating diagnosis was roughly 30%.19 Underdiagnosis was 
further demonstrated when comparing the clinicians’ esti-
mates for confirmed cases of AATD diagnosis to published 
prevalence: on average the clinicians’ estimates were 90% 
lower than the figures ascertained from epidemiological 
studies. When queried as to why this underdiagnosis 
exists, a large majority (76.9%) of clinicians cited a lack 
of awareness of AATD among primary care as the biggest 
obstacle. A significant number (15.4%) also stated no 
availability of treatment as another obstacle for diagnosis, 
presumably because in the absence of treatment some 
clinicians feel making a diagnosis is not worthwhile. 
Notably guidance on treatment varies worldwide.18,20
A potential factor worth considering as an obstacle to 
diagnosis is the availability of a nationwide AATD screen-
ing program; of the 13 countries represented in the survey 
only four had a screening program in place.19 The use of a 
screening program would theoretically cast a wide net for 
potential cases, especially those who are heterozygous for 
deficient alleles and may be asymptomatic or present with 
mild COPD symptoms. Table 1 considers whether AATD 
meets the classical criteria for screening, and more recent 
proposed adaptations to this following the advent of 
genetic technologies.21 Although population wide 
screening has drawbacks related to cost effectiveness, tar-
geted screening of at-risk groups and family screening 
both have the potential to be powerful tools in improving 
the diagnostic rate of AATD, recognized in the newer 
criteria, which appear to advocate a more targeted 
approach.
Table 1 shows that whilst some criteria for screening 
are met, not all are reached, regardless of which system is 
used.
All the clinicians surveyed in Europe had access to 
AAT serum concentration measuring and isoelectric focus-
ing for diagnosis, such that a screening programme could 
be set up. However, only 73% have access to gene sequen-
cing. Opening up this technology could have a dramatic 
impact on the incidence of AATD, especially in detecting 
heterozygous cases or those with very rare genetic var-
iants, as shown in a study from Canada.23 Whilst over 100 
mutations of the SERPINA1 gene have been described in 
the literature, diagnosis has been mostly restricted to the 
most pathogenic, PiSZ and PiZZ genotypes by many 
laboratories. Removing this obstacle by gene sequencing 
all potential cases could significantly address some aspects 
of the underdiagnosis problem, in that rarer alleles would 
be identified routinely, and the technology could be incor-
porated in some countries alongside other genetic testing 
programs. Sequencing would, however, add cost to screen-
ing, and this would need to be balanced against the poten-
tial value for a country of conducting such an intervention, 
as alluded to in Table 1. In Sweden, screening was intro-
duced for a short time, but the only impact at age 34 was 
on smoking uptake; no difference was seen in other pul-
monary parameters or symptoms.24 Cost-effectiveness 
modeling using lifetime horizon parameters has been 
done in COPD case finding,25 and similar methods might 
need to be employed to convince healthcare funders that a 
screening approach for AATD is affordable. Given the 
variable prevalence of AATD worldwide such studies 
would almost certainly need to be country or region 
specific.
Delays in Diagnosis: The Role of Public 
Health, Laboratory Methods, and 
Education
Another factor to consider as an obstacle to diagnosis is 
the time taken for diagnoses to be confirmed, with the 
majority of clinicians (60%) estimating diagnosis took 
longer than 5 years.19 One might speculate that this 
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diagnostic odyssey means potential cases are lost due to 
patients losing faith and not attending follow-up clinic 
visits. It is also fair to assume in that time span some 
patients’ health deteriorates to the point where they die 
before diagnosis is confirmed. These types of delays in 
diagnosis are seen to be common, as reported in Canada, 
where average diagnosis time was 7 years.26 There have 
been positive strides taken to address this obstacle in many 
locations. In Germany a public health campaign raising 
awareness for AATD testing and offering test kits signifi-
cantly improved case detection, albeit performing better in 
a selected rather than unselected population.27 In Spain a 
form of test kit which utilizes dried blood spots, hence is 
possible for patients to perform themselves, was also 
Table 1 Screening Criteria in Relation to AATD
Classic Screening Criteria Does AATD Meet This Criterion? Genomic Age Screening 
Criteria
Does AATD Meet This 
Criterion?
The condition sought should be an 
important health problem
Maybe: varies by prevalence, typically 
about 5% of COPD patients22
The screening program 
should respond to a 
recognized need
Probably
There should be an accepted 
treatment for patients
Sort of: augmentation is acceptable for the 
lung, nil for the liver
The objectives of screening 
should be defined at the 
outset
No, but would be 
possible with 
international consensus
Facilities for diagnosis and treatment 
should be available
Yes, in most countries There should be a defined 
target population
No, but international 
consensus could define, 
eg, family screening, 
people with COPD
There should be a recognizable latent 
or early symptomatic stage
Probably: most people are not very 
symptomatic until COPD progresses
There should be scientific 
evidence of screening 
program effectiveness
Not much; possible 
reduction in smoking 
uptake in Sweden17
There should be a suitable diagnostic 
test
Yes The program should integrate 
education, testing, and clinical 
services
Very few countries are 
fully set up like this, but 
could be addressed
Diagnostic test should be acceptable 
to the population
Yes There should be quality 
assurance (QA), with 
mechanisms to minimize 
potential risks of screening
Ongoing QA project in 
Europe. Ought to be 
possible in most 
countries
Natural history should be adequately 
understood
Partly; some factors determining 
describing progression are known but it is 
not fully explained in the lung. Less is 
known about the liver
The program should ensure 
informed choice, 
confidentiality, and respect 
for autonomy
Ought to be possible in 
most countries
There should be an agreed policy on 
whom to treat
No. Highly variable between countries 
with respect to many aspects including 
augmentation therapy18
The program should promote 
equity and access to screening 
for the entire target 
population
Ought to be possible in 
most countries
Cost of case-finding (including 
diagnosis and treatment) should be 
balanced in relation to expenditure on 
medical care overall
Debatable; most countries have systems 
that will address this
Program evaluation should be 
planned from the outset
International consensus 
on outcomes would be 
helpful first
Case-finding should be a continuing 
process
Variable by location The overall benefits of 
screening should outweigh 
the harm
Probably true
Not wholly met and likely to vary by location Majority met or possible to meet
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examined and found feasible.28 Lateral flow test kits (simi-
lar to a pregnancy test) have also been used internationally 
with success.29 Opportunistic testing at hospital admission 
for COPD has also shown promise in a small study.30
A review addressing areas for research within AATD 
also underlined the underdiagnosis problem; approxi-
mately 90% of cases were undetected.31 The authors indi-
cated that since AATD clinical presentation was so similar 
to other pulmonary pathologies, patients were often mis-
diagnosed. This would ring true when looking at recent 
epidemiological studies that estimated, globally, there are 
over 1.0 million individuals with the most severely defi-
cient genotypes, ie, PiSZ and PiZZ,5 yet clinicians still 
view it as a rare disease. The authors argue that, due to the 
wide variability in the severity of symptoms of AATD 
patients, a new diagnostic approach is required. As there 
is no universally accepted diagnostic algorithm, AAT 
serum concentration in COPD patients is widely used. 
Accounting for the effects of inflammation on AAT level 
(because AAT is an acute phase protein) by concurrent 
measurement of CRP is also advocated.32 However, even 
with the addition of CRP, use of levels to determine 
advanced testing could easily miss heterozygous indivi-
duals who exhibit greater variability in AAT serum con-
centration and yet could still be at risk of developing 
COPD. Use of genetic technologies as described above 
could overcome this limitation, albeit at considerable 
cost. Another approach using measurement of α1-globulin 
alongside liver function and inflammatory markers, as a 
means of determining whether genotyping is worthwhile 
has also been proposed.33
Although AATD has been thought of primarily as a 
pulmonary disease and most diagnoses are detected 
through symptoms of lung pathology, it is important to 
also understand the importance of liver disease as a diag-
nostic pathway; especially within neonates as AATD is 
their most common cause of liver disease.34,35 It is possi-
ble that screening at the neonatal level is unnecessary, but 
targeted testing of individuals who have exclusively liver 
disease (no COPD) may be even more valuable than test-
ing COPD patients; this approach may yield higher detec-
tion rates of AATD than testing COPD patients,31 albeit 
with varying prevalence depending on age. A review 
focused on improving the management of AATD in chil-
dren concluded that there should be greater awareness of 
the condition within pediatric medicine, especially in cases 
of liver disease of unknown etiology.34 The authors 
reviewed a variety of clinical presentations that could 
indicate PiZZ AATD including increased bilirubin, hepa-
tomegaly, hepatosplenomegaly, chronic hepatitis, and fail-
ure to thrive, and found neonatal cholestasis to be the most 
associated feature, with a screening study of 200,000 neo-
nates finding 17% of those with PiZZ genotype presenting 
with the pathology. The authors concede that, because a 
wide range of neonatal disorders cause liver disease, an 
AATD diagnosis is not always obvious. They suggest that 
to remove this obstacle to diagnosis, pediatricians should 
be made more aware of the hepatic pathology of AATD 
and understand that a correct and early diagnosis can put 
patients on the appropriate treatment path to help prevent 
developing severe lung disease. They also note the added 
benefit a neonatal diagnosis can provide in allowing par-
ents to avail themselves of the services of genetic counse-
lors. Table 2 summarizes the strategies tested to date to 
raise awareness and reduce delay in diagnosis.
Case-Finding Instead of Screening
As there is no defining clinical sign for AATD diagnosis, 
the use of targeted detection across a range of phenotypes 
has to be considered; this would be consistent with the 
more nuanced approach to screening now advocated 
(Table 1). It is conceivable that AATD could be identified 
through screening for other lung pathologies; for example, 
if small airways disease (SAD) or emphysema were seen 
on a CT scan done for lung cancer screening it might 
trigger tests for COPD38 and AATD. Typically cancer 
Table 2 Methods to Reduce Under-Diagnosis or Delayed Diagnosis of AATD
Strategy Results of Implementation Citation
Public health campaign Rate of detection higher, but link to free testing means effect cannot be attributed to campaign alone 27
Point of care/patient led 
testing
Rate of AATD detection higher than in general clinics, but most studies did not have a formal control 27–29
Education of physicians Increase in AATD testing of COPD patients after written materials/quiz (74–81%; P<0.05) 
Greater knowledge of AATD, self-reported increase in testing after educational video
36 
37
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screening focuses on heavy smokers though, so there 
would be risks to this approach, mainly missing cases 
who have never smoked or have low smoke exposure, 
and in some countries questions have been raised about 
the cost-effectiveness of such CT based programs.39 Case 
finding for AATD in individuals with COPD diagnosed at 
a young age, with low smoke exposure, or with a family 
history of COPD would also be an obvious method, con-
sistent with most current international guidance, but inade-
quately implemented in most countries at present. For 
example in the UK only 2.2% of people with COPD 
below the age of 60 had been tested for AATD in one 
primary care group.40 Importantly case finding for COPD 
has been found to be feasible, beneficial, and cost-effective 
in primary care, suggesting that adding an extra step to test 
for AATD in a subset of people is something that might be 
practical and affordable.25,41
The parallel process for liver disease would be to 
screen people who appear to have liver fibrosis. Serum 
concentration of gamma glutamyl transferase (GGT) was 
seen to be raised in children with PiZZ genotype,42 
although it is not a perfect marker in adults since it may 
also relate to lung disease,43 and classically rises with 
alcohol consumption as well. The possibility of using 
liver pathology as a signpost for AATD via elastography 
as an imaging biomarker has also been investigated; a 
comparative study concluded that increased shear wave 
speed, as determined by a variety of elastography techni-
ques, correlated significantly with AATD diagnosis 
(P<0.009).44 A threshold of 7.9 kPa seemed to relate 
well to diagnosis and histological fibrosis in cohort 
studies.45–47 However the utility of widespread AATD 
case findings based on elastography or liver function 
tests in the blood has not been conducted.
One novel way of detecting subgroups within COPD or 
liver fibrosis who might be more at risk of having AATD 
could be use of biomarkers that detect disease progression 
in either the lung or the liver. Desmosine and isodesmo-
sine, both products of elastin degradation, are raised in 
AATD COPD patients48 and could hold promise as a 
biomarker for measuring progression of AATD-caused 
COPD.49 Results from the RAPID/RAPID Extension trial 
showed a correlation between desmosine/isodesmosine 
levels and CT lung density used as a clinical marker of 
progression of emphysema.50 Ma et al50 suggested that 
desmosine/isodesmosine levels may therefore be useful 
in evaluation of therapeutic agents that can decrease elas-
tin degradation and lung matrix injury. Z-AAT polymers 
could also be a potential marker to confirm at-risk patients 
with AATD,51 although further research is needed because 
little is known about how Z-AAT polymers are synthesized 
and secreted, in comparison to M-AAT polymers, nor 
which risk groups altered levels mark out most clearly. 
The use of imaging biomarkers has also been investigated 
for identifying and evaluating lung disease in AATD. A 
review conducted into the role computed tomography 
played in the management of AATD confirmed that CT 
image assessment could be used to identify AATD-related 
emphysema in the lungs and could map disease progres-
sion, thereby allowing predictions to be made on the 
appropriateness of therapy.52 Clearly use of CT needs to 
be balanced against risks of radiation exposure and also of 
cost; secondary analysis of scans being done for another 
reason (eg, cancer screening) would be a more sensible 
approach than using CT specifically for emphysema 
detection.
The consensus in the literature is that patients present-
ing with either liver or lung disease come into contact with 
many healthcare professionals, over long periods of time, 
so opportunities for diagnosis exist. Figure 1 illustrates a 
possible ideal health system maximizing detection and 
onward referral of patients at risk of deterioration. After 
a diagnosis has been made patients should be followed-up 
3–12 monthly with lung function and other clinical assess-
ments, as described by the European Respiratory 
Society.13
Treatment
Determining the prognosis can be difficult in AATD, 
because of the variability of presentation and subsequent 
progression, and it is conceivable that clinicians only feel 
there is benefit to early diagnosis if they can then prog-
nosticate, thus know who to treat. The use of multifaceted 
tools or scores to evaluate COPD patients has been 
explored, in which the BODE score (BMI, airflow obstruc-
tion, dyspnoea, exercise capacity) was better at differen-
tiating survival than forced expiratory volume 1 (FEV1) 
alone or the GOLD classification (Global Initiative for 
COPD),53 and shows a similar pattern in AATD.54 
However scores like this generally perform better at popu-
lation than individual level. Once prognosis has been 
established then efforts to treat AATD can be explored. 
Treatment of AATD has traditionally been lung-centric 
and has aimed to delay the onset of emphysema, reduce 
the frequency of pulmonary exacerbations, and improve 
quality-of-life. This section will not just encompass those 
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therapies targeting lung disease, but also future therapies 
to alleviate AATD-related liver disease.
Lung Disease
The treatment options available to AATD patients at pre-
sent are broadly similar to patients who have COPD unre-
lated to AATD, with symptoms being managed by 
bronchodilators, inhaled steroids, pulmonary rehabilita-
tion, possibly lung volume reduction treatment, and lung 
transplantation.55 The only specific AATD treatment 
licensed worldwide has been plasma-purified AAT, given 
intravenously; this treatment has been coined augmenta-
tion therapy as it augments the patient’s deficient AAT 
serum concentration. Of these, the interventions that 
might be applicable to patients diagnosed early at present 
are inhaled therapies, rehabilitation, and augmentation.
Inhaled Therapies
In the case of an AATD patient diagnosed early, we would 
hope that lung function will be less impaired (if at all) 
hence augmentation therapy might not be necessary, and 
certainly is not recommended in most international 
guidance.13,20 The main goal is to prevent the development 
of lung disease, and risk factors for emphysema progres-
sion should be assessed as early as possible. There are 
limited studies looking at the benefits of inhaled therapies 
in AATD, but those patients with COPD are treated fol-
lowing COPD guidelines so we would expect evidence in 
usual COPD to apply. Inhaled therapies are prescribed 
according to the degree of breathlessness and inhaled 
corticosteroids have been shown to reduce FEV1 decline 
in PiZZ AATD patients with persistent eosinophilia.56
Augmentation
Augmentation therapy has had significant beneficial effects 
for patients in trials; the RAPID trial found lung density 
decline, by quantitative computed tomography (CT), in trea-
ted patients was significantly slower than in untreated 
patients, and earlier trials showed trends in this direction.57 
However, it is important to note that this was only observed 
for quantitative CT measurements performed at total lung 
capacity (TLC) alone rather than functional residual capacity 
(FRC) alone or TLC and FRC combined. A systematic 
review and meta-analysis also found noteworthy results 
related to augmentation therapy;55 in pooled data from 
three RCTs for a total of 320 participants where lung density 
was measured via CT scan, annual deterioration in lung 
density was significantly less on augmentation than on pla-
cebo with a difference of 0.79 g/L/year. However, this was 
the only significant result, with no effect demonstrated on 
Figure 1 Optimized detection of AATD, In the above system patients or healthcare professionals could access AATD testing, and it would also be automatically triggered by 
identification of emphysema or liver fibrosis on tests done for other reasons. Educated healthcare professionals would always test for AATD in relevant respiratory and 
hepatic presentations, and patients aware of (for example) a family history of AATD or COPD would know that they should get tested and would access it themselves either 
before or after a healthcare professional saw them. Referral to specialist centers would occur early after a positive laboratory test.
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secondary outcomes including lung function and quality-of- 
life. Nevertheless it is important as change in lung density by 
quantitative CT is related to mortality in AATD.58 Another 
meta-analysis of clinical studies found that decline in FEV1 
was 23% slower in patients receiving augmentation.59 
However this decline was only significant in the subset of 
patients with predicted FEV1 of 30–65%, those with <30% 
or >65% predicted were not significant. This suggested that 
augmentation therapy was only appropriate for those AATD 
patients with moderate lung disease, although it may also be 
argued that it is the ongoing rate of deterioration rather than 
a single baseline value that is of relevance for augmentation, 
since it only modifies ongoing decline.
Whilst most international guidelines set a threshold 
FEV1 for receipt of augmentation therapy,20 these vary and 
having any threshold at all may be inappropriate given that 
response to augmentation appears to be independent of base-
line FEV1.60,61 However there is little evidence that aug-
mentation therapy can improve patient outcomes in early 
disease, since the majority of RCTs excluded patients with 
higher levels of lung function, which are likely to occur in 
those with early disease (summarized in Table 3). 
Theoretically similar effects might be expected in any patient 
with emphysema, but evidence to support this is lacking.
Table 3 shows that inclusion criteria excluded most 
patients likely to have early disease, with upper limits on 
FEV1 of 70–80% predicted. Patients with FEV1 ≤70% in 
the context of emphysema would likely have moderate 
severity (or worse) COPD; those ≥80% would be mild 
COPD. Whilst it is possible someone could be newly 
diagnosed with this level of lung function impairment 
this may not represent early disease, given that delay in 
diagnosis is common. Thus there is little evidence from 
RCTs of efficacy of augmentation in early disease.
One approach to clinical decision-making about augmenta-
tion might be to use the treatment in any patient who has lung 
disease which appears to be progressing;65 this would of course 
require a period of observation, which many patients and 
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clinicians would be reluctant to do in the presence of sympto-
matic disease. However in cases diagnosed early, where there 
might be few symptoms, a period of observation might be 
more acceptable; this requires exploration with the patient 
and physician community, particularly in countries where aug-
mentation is already widely available. Selection of the optimal 
method to pick up decline would also be helpful; whilst CT 
densitometry has proven best at this in trials regular use of CT 
would have logistical issues in many centers, and potential 
harms from regular radiation exposure. Identification of phy-
siological or blood markers would be more desirable; in our 
own work gas transfer appeared to be much better than FEV1 
at detecting densitometry defined emphysema progression, for 
instance.58
When reviewing the results from a European expert survey 
the provision of augmentation therapy for AATD patients is 
inconsistent; Germany and France each have approximately 
60% of their patients receiving the treatment while the UK and 
the Netherlands have 0% and 5%, respectively.19 Reasons for 
these disparities include differences in regulations around 
augmentation therapy; countries which granted approval to a 
specific named brand drug (Prolastin) had higher uptake of 
augmentation therapy than countries without approval. Other 
commonly cited obstacles to augmentation were infusion time 
(33.3%), and frequency of infusions (16.7%), and in many 
health systems cost will also be a factor, which will be greater 
if treatment is extended to early stages.19 This would suggest 
that augmentation therapy has enough downsides that a search 
for alternatives is required. Indeed many studies of alternative 
strategies are under way, which have been reviewed 
elsewhere.66 Many of the trials of alternative lung directed 
therapies are recruiting patients in earlier stages of disease 
than augmentation is typically used; specific subgroup ana-
lyses by disease stage may be of interest in order to determine 
which treatments should/could be used at each stage. Table 4 
summarizes currently recruiting studies and the severity stages 
applicable.
Whilst these new treatments have been reviewed 
extensively,66 it is worth considering them briefly here for 
their potential in early disease. A synthetic recombinant AAT 
Table 4 RCTs of Treatments Ongoing and Potentially Applicable to Early Disease
Intervention Eligible to Enroll
Drug Class and/or Name Emphysema with Normal 
Spirometry
Mild COPD (FEV1 
>80%)
Study Status NCT 
Number
ADVM-043 gene therapy (ADVANCE) Yes Yes Completed 02168686
Recombinant adeno-associated virus vector 
expressing human AAT
Yes Yes Completed 01054339
Alpha-1 proteinase inhibitor solution (GLASSIA) Yes Yes Active, not 
recruiting
02525861
VX-814 Yes Yes Terminated 04167345
Oral neutrophil elastase inhibitor, Alvelestat 
(ATALANTa)
Yes Yes Recruiting 03679598
Recombinant human AAT with fusion protein 
(INBRX-101)
Yes Yes – for some 
dosage arms
Recruiting 03815396
Inhaled Alpha-1-Antitrypsin (InnovAATe) Yes Yes Recruiting 04204252
VX-864 Yes Yes Recruiting 04474197
Oral neutrophil elastase inhibitor, Alvelestat 
(ASTRAEUS)
Yes Yes Recruiting 03636347
Alpha-1 proteinase inhibitor (SPARTA)(68) No No Recruiting 01983241#
Carbamazepine (Tegretol XR) Yes Yes Recruiting 01379469*
Subcutaneous injection of ARO-AAT Yes Yes Recruiting 03946449*
Notes: *Denotes study relevant only to liver disease. #Indicates lung inclusion criteria that may exclude early disease, depending on the definition applied.
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(rAAT) fused with another molecule to reduce any immune 
reactions with non-human proteins is being investigated in a 
dose-escalating Phase I trial; this would have similar limita-
tions to augmentation in that it requires intravenous infusions, 
which might not be popular with relatively asymptomatic 
patients, although the frequency is likely to be less, which 
may be helpful. In order to tackle the obstacles associated 
with intravenous augmentation, inhaled augmentation may 
have promise, and is in Phase 3 testing. Another avenue to 
consider in AATD treatment is that of addressing antiprotease- 
protease balance – instead of increasing antiprotease activity 
(ie, AAT) this decreases protease activity (ie, neutrophil elas-
tase). Clinical trials are ongoing that use a synthetic neutrophil 
elastase inhibitor and will measure neutrophil elastase activity 
through measuring desmosine/isodesmosine concentration as a 
marker of neutrophil elastase action. This mechanism would 
potentially be applicable and modifiable in all disease stages. 
Treatments which address raising native AAT levels, such as 
small molecule approaches that prevent polymerization, would 
also be attractive in early lung disease for similar reasons. 
Notably the current trials targeting these two mechanisms are 
oral, so may be more acceptable to patients with few symp-
toms, such as those diagnosed at an early stage.
Liver Disease
Whilst augmentation therapy has proven effective at decel-
erating severe lung disease there are many manifestations 
of AATD that require their own specialist treatment, the 
most pertinent of these is liver disease. A systematic 
review has reported the prevalence and natural history of 
AATD associated liver disease, being around 15% on 
average with a bimodal distribution peaking in childhood 
and later life.68 This indicates two different tracks to 
development of significant disease, one rapid in childhood 
and the other much more indolent. This has implications 
for what we would consider “early diagnosis” in the liver – 
for children this would presumably have to be neonatal 
screening, whilst for adults it might mean those with 
abnormal LFTs or elastography (as described in the case 
finding section). The authors noted that when carrying out 
their search the only available treatment option was liver 
transplantation, which had good outcomes in both children 
and adults with AATD,68 though this is of course a treat-
ment reserved for advanced disease. It should be noted 
however that the wider issues of relative shortage of 
pediatric organs for transplantation69 might preclude 
much in the way of benefit from early diagnosis for the 
minority of patients who will develop clinically significant 
childhood liver disease. Early detection of more indolent 
adult liver disease could have more potential for benefit, 
particularly with the newer drugs that are becoming avail-
able in this field.
There are four novel therapeutic areas that could be appro-
priate for treating early onset liver disease, which function by 
interfering in accumulation of Z-AAT polymers in the liver. 
One of these therapeutic areas is gene editing technologies, 
namely small interfering RNA (siRNA) and clustered regu-
larly interspaced short palindromic repeats (CRISPR/Cas9). 
The siRNA molecules target RNA that encodes AAT protein 
and thus reduce its production and therefore accumulation. 
CRISPR/Cas9 is being used to edit the SERPINA1 gene to 
stop producing Z-AAT; both of these methods have proven 
effective in mouse models and clinical trials have been started. 
The second therapeutic area is autophagic enhancers which 
increase the autophagy and disposal of Z-AAT polymers; they 
have also been moved to the clinical trial stage. Chaperone 
molecules were another therapeutic area trialed; these work by 
inhibiting enzymes related to histones that then increase Z- 
AAT secretion from the liver. After the success of 4-phenylbu-
terate (4-PBA) in mouse models where a two-fold increase in 
circulating AAT levels was seen70 it was hypothesized that this 
may be a promising therapy to prevent emphysema and reduce 
accumulation of Z protein within the liver.71 However, preli-
minary trials failed to show an increase in AAT blood levels in 
AATD71 and also resulted in significant adverse events,72 
indicating that further research is needed in this area. Finally 
there is a monoclonal antibody that has a structure designed to 
fit into the reactive loop of Z-AAT and thus prevent aggrega-
tion on the polymers and thus liver accumulation.73 Some such 
molecules have been tested in mammalian cell lines.74 Each of 
these drugs has potential to slow down, or prevent onset of liver 
disease, and those which also elevate AAT levels in the blood 
have some potential to treat or prevent lung disease. However, 
the rate of progression of adult liver disease, and the optimal 
non-invasive way of monitoring this to select patients at risk of 
rapid decline, and in whom newer treatments would be 
expected to have greater benefit requires further research in 
large cohorts.
Currently, therefore, it would be harder to target drugs 
to early liver disease as we are less certain which patients 
have disease with potential to progress, and how to pick up 
progression early. Similar issues to treatment of early 
disease, such as cost and willingness of patients to take 
drugs by non-oral routes if asymptomatic would also apply 
to management of early liver disease.
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Conclusion
The obstacles to early diagnosis and treatment could be 
seen as similar in nature to one another. A lack of aware-
ness of the condition, naturally arising from its rarity, has 
led to a paucity of treatment research and development 
until recently; meaning there is only one disease-specific 
therapy, augmentation therapy, available at present. Even 
this treatment has had trouble convincing regulators of its 
efficacy, thus erecting barriers for patients trying to 
access it. The nature of the disease, presenting with two 
different pathologies, has made developing a universal 
treatment difficult. Detecting all cases of AATD and 
showing its true prevalence in our population would not 
only give clinical researchers the chance to conduct large 
RCTs, but also sound the alarm to the research commu-
nity at large that there is action needed to be taken in 
helping remove the significant disease burden AATD 
places on patients. To address this is likely to require 
public health programs, investment in validated test stra-
tegies accessible to all clinicians, as well as widespread 
education of the physician and patient community, espe-
cially in areas where the disease is most likely to present 
– pulmonology, hepatology, and pediatrics, alongside pri-
mary care clinicians who conduct COPD reviews in most 
countries.
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